Biohaven Ltd.
BHVN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 53.1%, free cash flow grew 49.1% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow BHVN
Biohaven Ltd. (BHVN) EV/Sales
As of 16 October 2026, Biohaven Ltd. (BHVN) trades at a EV/Sales of 1.6×. Over the past ten years it has ranged from 0.0× (December 2020) to 59.5× (June 2021); the current reading is higher than 61% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2021 | 10.1× | (80.77%) |
| FY2020 | 52.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2022 | 6.1× | 10.60% |
| Mar 2022 | 5.5× | (45.89%) |
| Dec 2021 | 10.1× | (44.94%) |
| Sep 2021 | 18.4× | (44.85%) |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ZBIO Zenas BioPharma, Inc. compare | n/m |
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| BHVN Biohaven Ltd. | 1.6× |
| VIR Vir Biotechnology, Inc. compare | 3.7× |
| NUVB Nuvation Bio Inc. compare | 6.7× |
| URGN Urogen Pharma compare | 9.7× |
| SEPN Septerna, Inc. compare | 12.7× |
| XNCR Xencor, Inc. compare | 13.4× |
| MESO Mesoblast Limited compare | 137× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)